T. Mark Iwicki's Insider Trades & SAST Disclosures
T. Mark Iwicki's most recent trade in Q32 Bio Inc. was a trade of 37,222 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 24, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern T. Mark Iwicki.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Q32 Bio Inc. | Mark Iwicki T. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 37,222 | 0 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 37,222 | 37,222 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Mark Iwicki T. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 25,534 | 0 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | T. Iwicki Mark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 25,534 | 25,534 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Iwicki T. Mark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 7,615 | 7,615 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Iwicki T. Mark | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Feb 2025 | 7,615 | 0 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Mark T. Iwicki | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 602,346 | 602,346 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Mark T. Iwicki | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 4,373,857 | 4,373,857 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Mark T. Iwicki | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 1,794,291 | 1,794,291 | - | - | Stock Option (Right to Buy) | |
| Kala Pharmaceuticals Inc | Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 99,500 | 99,500 | - | - | Stock Option (right to buy) | |
| Kala Pharmaceuticals Inc | Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 22,100 | 285,855 (0%) | 0% | 0 | Common Stock | |
| Kala Pharmaceuticals Inc | Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 7.63 per share. | 06 Jan 2025 | 5,779 | 280,076 (0%) | 0% | 7.6 | 44,094 | Common Stock |
| Kala Pharmaceuticals Inc | Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 4.75 per share. | 26 Jun 2024 | 15,168 | 263,755 (0%) | 0% | 4.8 | 72,048 | Common Stock |
| Akero Therapeutics Inc | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2024 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Third Harmonic Bio Inc | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 20,000 | 20,000 | - | - | Director Stock Option (right to buy) | |
| Jade Biosciences Inc | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Kala Pharmaceuticals Inc | Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 6.09 per share. | 31 May 2024 | 7,392 | 278,923 (0%) | 0% | 6.1 | 45,017 | Common Stock |
| Merus N.V | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 8,844 | 8,844 | - | - | Share Option (right to buy) | |
| Q32 Bio Inc. | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 25,534 | 25,534 | - | - | Stock Option (Right to Buy) | |
| Kala Pharmaceuticals Inc | Mark Iwicki T. | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 64,500 | 64,500 | - | - | Stock Option (right to buy) | |
| Kala Pharmaceuticals Inc | T. Mark Iwicki | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 14,300 | 290,854 (0%) | 0% | 0 | Common Stock | |
| Kala Pharmaceuticals Inc | Iwicki Mark T. | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 6.73 per share. | 04 Jan 2024 | 4,539 | 286,315 (0%) | 0% | 6.7 | 30,547 | Common Stock |
| Akero Therapeutics Inc | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Merus N.V | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 14,414 | 14,414 | - | - | Share option (right to buy) | |
| Third Harmonic Bio Inc | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 16,250 | 16,250 | - | - | Stock Option (right to buy) | |
| Jade Biosciences Inc | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Merus N.V | Mark T. Iwicki | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.57 per share. | 14 Apr 2023 | 36,944 | 36,944 (0%) | 0% | 6.6 | 242,722 | Common Shares |
| Merus N.V | Mark T. Iwicki | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2023 | 36,944 | 0 | - | - | Share Option (right to buy) | |
| Merus N.V | Mark T. Iwicki | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.97 per share. | 14 Apr 2023 | 36,632 | 73,576 (0%) | 0% | 8.0 | 291,957 | Common Shares |
| Merus N.V | Mark T. Iwicki | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2023 | 36,632 | 0 | - | - | Share Option (right to buy) | |
| Kala Pharmaceuticals Inc | Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 1,512 | 1,512 | - | - | Stock Option (Right to Buy) | |
| Third Harmonic Bio Inc | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 35,413 | 35,413 | - | - | Employee Stock Option (right to buy) | |
| Third Harmonic Bio Inc | Mark T. Iwicki | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 06 Mar 2023 | 35,413 | 0 | - | - | Employee Stock Option (right to buy) | |
| Third Harmonic Bio Inc | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 13,667 | 13,667 | - | - | Employee Stock Option (right to buy) | |
| Third Harmonic Bio Inc | Mark T. Iwicki | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 06 Mar 2023 | 13,667 | 0 | - | - | Employee Stock Option (right to buy) | |
| Kala Pharmaceuticals Inc | Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2023 | 41,700 | 46,164 (0%) | 0% | 0 | Common Stock | |
| Kala Pharmaceuticals Inc | Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 28.54 per share. | 04 Jan 2023 | 198 | 45,966 (0%) | 0% | 28.5 | 5,651 | Common Stock |
| Third Harmonic Bio Inc | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2022 | 13,667 | 13,667 | - | - | Stock Option (right to buy) | |
| Kala Pharmaceuticals Inc | Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 6.52 per share. | 26 Oct 2022 | 561 | 4,464 (0%) | 0% | 6.5 | 3,658 | Common Stock |
| Kala Pharmaceuticals Inc | Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 0.37 per share. | 27 Jun 2022 | 7,975 | 251,183 (0%) | 0% | 0.4 | 2,951 | Common Stock |
| Jade Biosciences Inc | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Merus N.V | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2022 | 16,604 | 16,604 | - | - | Share option (right to buy) | |
| Kala Pharmaceuticals Inc | Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 775,000 | 775,000 | - | - | Stock Option (right to buy) | |
| Kala Pharmaceuticals Inc | Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 1.30 per share. | 03 Jan 2022 | 9,518 | 259,158 (0%) | 0% | 1.3 | 12,373 | Common Stock |
| Kala Pharmaceuticals Inc | Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 1.80 per share. | 26 Oct 2021 | 27,598 | 268,676 (0%) | 0% | 1.8 | 49,676 | Common Stock |
| Kala Pharmaceuticals Inc | Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 5.77 per share. | 28 Jun 2021 | 7,586 | 296,274 (0%) | 0% | 5.8 | 43,771 | Common Stock |
| Akero Therapeutics Inc | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| Merus N.V | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 6,120 | 6,120 | - | - | Share option (right to buy) | |
| Jade Biosciences Inc | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2021 | 76,747 | 76,747 | - | - | Stock Option (Right to Buy) | |
| Jade Biosciences Inc | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2021 | 42,200 | 42,200 | - | - | Stock Option (Right to Buy) | |
| Jade Biosciences Inc | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2021 | 39,550 | 39,550 | - | - | Stock Option (Right to Buy) | |
| Pulmatrix Inc | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Kala Pharmaceuticals Inc | Mark T. Iwicki | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 303,000 | 303,000 | - | - | Stock Option (right to buy) | |
| Kala Pharmaceuticals Inc | Mark T. Iwicki | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 76,000 | 303,860 (0%) | 0% | 0 | Common Stock | |
| Kala Pharmaceuticals Inc | Mark T. Iwicki | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2020 | 178,300 | 227,860 (0%) | 0% | 0 | Common Stock | |
| Merus N.V | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 8,631 | 8,631 | - | - | Share Option (right to buy) | |
| Kala Pharmaceuticals Inc | Mark T. Iwicki | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 49,560 | 49,560 (0%) | 0% | 0 | Common Stock | |
| Akero Therapeutics Inc | Mark T. Iwicki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2020 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges